All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

May 10th 2024

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.

Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC

May 10th 2024

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

May 10th 2024

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.

NICE Recommends Oncotype DX for Guiding Chemotherapy Decisions in Early-Stage, HR+/HER2– Breast Cancer

May 10th 2024

NICE recommends Oncotype DX to guide chemotherapy decisions in early-stage, HR-positive, HER2-negative breast cancer involving up to 3 positive nodes.

New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment

May 10th 2024

Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer

SNB-101 Receives FDA Fast Track Designation for SCLC

May 10th 2024

SNB-101 has received FDA fast track designation for potential use in patients with small cell lung cancer.

First-Line Versamune HPV Plus Pembrolizumab Meets BOR End Point in Recurrent/Metastatic HPV16+ HNSCC

May 10th 2024

First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024

During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

May 9th 2024

Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer

May 9th 2024

Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.

Mohty Shares Key Takeaways From the 50th Annual EBMT Meeting, Highlighting Advances in GVHD

May 9th 2024

Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EBMT Meeting, focusing on ongoing efforts within the GVHD treatment arena.

New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy

May 9th 2024

A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

May 9th 2024

Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors

May 9th 2024

The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.

FDA Grants Breakthrough Device Designation to At-Home Cervical Cancer Screening Test

May 9th 2024

The FDA has granted a breakthrough device designation to Teal Wand, an at-home screening test for cervical cancer.

Improved Survival in Randomized Trials: A Meaningful Outcome but Increasingly Difficult to Demonstrate

May 9th 2024

Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease

May 9th 2024

Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.

IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer

May 8th 2024

China's NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma.

Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV

May 8th 2024

Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.